![April Manness](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
April Manness formerly worked at Luminor Medical Technologies, Inc., as Chief Financial Officer, Luminor Medical Technologies, Inc., as Chief Financial Officer in 2011, Kane Biotech, Inc., as Interim Chief Financial Officer from 2011 to 2012, and DiaMedica Therapeutics, Inc., as Chief Financial Officer.
Former positions of April Manness
| Companies | Position | End |
|---|---|---|
| KANE BIOTECH INC. | Director of Finance/CFO | 01/01/2012 |
Luminor Medical Technologies, Inc.
 Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Director of Finance/CFO | 23/12/2011 |
| DIAMEDICA THERAPEUTICS INC. | Director of Finance/CFO | - |
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Director of Finance/CFO | 17/10/2007 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
4
1st degree connections
3
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services | Commercial Services |
Kane Biotech, Inc.
 Kane Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that manufactures animal health oral care products | Commercial Services |
DiaMedica Therapeutics, Inc.
 DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
- Stock Market
- Insiders
- April Manness
